Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for BRAF V600E-mutant non-small-cell lung cancer, drawn from the whole corpus: 2 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No randomised trial compares BRAF plus MEK inhibitors with chemoimmunotherapy first line or settles the sequence.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Non-V600 BRAF mutations, half of cases, have no approved targeted therapy.
Resistance through MAPK reactivation has no established next step.
Nothing recorded yet.
Nothing recorded yet.
Background: Drug resistance (primary and acquired). Also on OnCo: Resistance atlas · Lines of therapy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 7 changes by month →When this page itself was last checked or edited.
BRAF V600E NSCLC with binimetinib
Response rate 75% (treatment-naive, n=59) and 46% (previously treated, n=39); FDA approval October 2023.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
With trametinib: BRAF V600E/K metastatic melanoma; later adjuvant melanoma, BRAF V600E NSCLC, anaplastic thyroid cancer, tumour-agnostic solid tumours and paediatric low-grade glioma